AbstractAnkyrin-R provides a key link between band 3 and the spectrin cytoskeleton that helps to maintain the highly specialized erythrocyte biconcave shape. Ankyrin deficiency results in fragile spherocytic erythrocytes with reduced band 3 and protein 4.2 expression. We use in vitro differentiation of erythroblasts transduced with shRNAs targeting ANK1 to generate erythroblasts and reticulocytes with a novel ankyrin-R ‘near null’ human phenotype with less than 5% of normal ankyrin expression. Using this model, we demonstrate that absence of ankyrin negatively impacts the reticulocyte expression of a variety of proteins, including band 3, glycophorin A, spectrin, adducin and, more strikingly, protein 4.2, CD44, CD47 and Rh/RhAG. Loss of band 3, which fails to form tetrameric complexes in the absence of ankyrin, alongside GPA, occurs due to reduced retention within the reticulocyte membrane during erythroblast enucleation. However, loss of RhAG is temporally and mechanistically distinct, occurring predominantly as a result of instability at the plasma membrane and lysosomal degradation prior to enucleation. Loss of Rh/RhAG was identified as common to erythrocytes with naturally occurring ankyrin deficiency and demonstrated to occur prior to enucleation in cultures of erythroblasts from a hereditary spherocytosis patient with severe ankyrin deficiency but not in those exhibiting milder reductions in expression. The identification of prominently reduced surface expression of Rh/RhAG in combination with direct evaluation of ankyrin expression using flow cytometry provides an efficient and rapid approach for the categorization of hereditary spherocytosis arising from ankyrin deficiency.
The ankyrins are a family of structural adaptor proteins that link membrane proteins to the cytoskeleton in a diverse range of cell types where they play a critical role in the formation and organization of physiologically important membrane proteins within specialized membrane microdomains.1 Canonical ankyrins have a modular domain organization with an N-terminal membrane binding domain containing 24 ANK repeats (1–24), followed by a central spectrin binding domain, a death domain and a C-terminal regulatory domain.2 Erythrocyte ankyrin (or ankyrin-R), alongside protein 4.2, links the tetrameric band 3-based multiprotein complex to the underlying spectrin cytoskeleton via associations with both the D2 and D3-4 regions of the ankyrin membrane binding domain.3 Ankyrin-R can also associate with other erythrocyte membrane proteins, including CD44,4 NaKATPase5 and RhAG.6 RhAG is a 50kDa glycosylated NH3 and CO2 membrane transport protein87 that together with the Rh proteins RhCe and RhD forms the core of the Rh subcomplex that also contains CD47, LW and GPB.9 Evidence supporting the interaction between RhAG and ankyrin includes a drop in RhAG expression in the nb/nb mouse with ankyrin deficiency, an interaction of the C-terminal tail of RhAG and the D2 subdomain of the ankyrin membrane binding domain in vitro, and the presence of the RhAG mutation D399A, shown to abrogate direct ankyrin binding in vitro in a patient with Rhnull syndrome.6
In humans, mutations in the ankyrin-R gene are responsible for 50% of hereditary spherocytosis (HS) cases,1110 a form of hemolytic anemia affecting 1 in 2000 people of Northern European ancestry.12 Although mutations in the ANK1 gene that result in hereditary spherocytosis are relatively prevalent, such mutations are most commonly heterozygous in nature and encode an array of complex alterations that include substitutions within specific binding sites and the generation of novel spliced or truncated protein products in addition to partial protein deficiency. This heterogeneity complicates the identification of secondary protein deficiencies that result from reduced ankyrin expression in human red blood cells and the corresponding insight into the role that this protein plays in the generation of the unique erythrocyte membrane cytoskeletal architecture. Reduced expression of the ankyrin binding proteins band 3 and protein 4.2 has been noted in these patients,1513 and in murine models of ankyrin deficient HS, secondary protein deficiencies of GPA, protein 4.2 and Rh, but not band 3 or GPC, were observed.16 However, more extensive characterization of the membrane protein composition in humans, including the effect on RhAG and other putative ankyrin associated proteins, is so far lacking.
A more detailed assessment of the importance and role that ankyrin-R protein expression plays in directing the development and composition of the human erythrocyte membrane is complicated by the absence of a naturally occurring null phenotype for this protein. In this study, we employ lentiviral shRNA transduction of primary erythroid cells and demonstrate the ability to deplete ankyrin-R expression to a level considerably lower than that observed in vivo.17 These cells were used to address the influence that ankyrin deficiency exerts on the membrane composition of the erythrocyte and developing erythroblast membrane, and to gain mechanistic insight regarding the loss of dependent proteins in its absence. The observed reduction in the plasma membrane expression of the core Rh complex components Rh and RhAG was confirmed on red blood cells from patients with HS due to mutations in ANK1. Furthermore, we propose a flow cytometry based strategy for easy identification of HS erythrocytes with ankyrin deficiency that could be used to direct diagnoses of HS molecular genetic defects.
Donor and patient blood
Platelet apheresis waste blood (NHSBT, Bristol, UK) from healthy donors or peripheral blood from patients previously diagnosed with HS because of a mutation in ANK1 were obtained with written informed consent for research use in accordance with the Declaration of Helsinki and approved by Bristol Research Ethics Committee Centre reference 12/SW/0199, as previously described.18
Erythroid cell culture and lentiviral transduction
Briefly, CD34 cells were purified from peripheral blood mononuclear cells using Magnetic Activated Cell Sorting (Miltenyi Biotec) following the manufacturer’s instructions, cultured for three days in Stemspan (Stem Cell Technologies) supplemented with SCF (100 ng/mL), Epo (2 U/mL, Bristol Royal Infirmary, UK), dexamethasone (1 μM, Sigma), IGF-1 (40 ng/mL, R&D Systems), cholesterol-rich lipids (40 μg/mL, Sigma) and 1 ng/mL IL-3 (R&D Systems): Phase 1. After three days, 50 μL concentrated lentivirus was added per 1×10 cells in expansion medium - IMDMExp (Phase 2), as previously described,18 supplemented with 8 μg/mL polybrene. After 20 h, the cells were washed 3 times in PBS and plated in fresh IMDMExp. Erythroblasts were further expanded and differentiated (Phase 3), as previously described.18 Lentiviral transduction of erythroblasts was performed as previously described using pLKO.1 vector with puromycin selection. Broad Institute Repository shRNA sequences TRCN0000083720 (shRNA 1) and TRCN0000083721 (shRNA 2) targeting ANK1 were used in preliminary experiments and TRCN0000083720 used unless otherwise stated.
Flow cytometry and FACS
Flow cytometry and FACS on cultured erythroid cells and erythrocytes was performed as previously described.18 For assessment of ankyrin levels by flow cytometry, donor and patient erythrocytes were fixed with 1% paraformaldehyde + 0.0075% glutaraldehyde in PBS supplemented with 1 mg/mL BSA (PBSAG), 2 mg/mL glucose for 10 min at room temperature, permeabilized with 0.05% Triton X-100 for 2 min, centrifuged for 3 min at 500 G, washed once in PBSAG, re-suspended in PBSAG containing 4% BSA, and stained sequentially with BRIC272 (anti-ankyrin) and APC-conjugated polyclonal anti-mouse IgG (Biolegend), as described.18 Pronase epitope recovery experiments were performed as previously described.19 A list of antibodies used in this study is provided in the Online Supplementary Table S1. Data were acquired on a MACSQuant flow cytometer and analyzed using FlowJo v.7.6.5 (FlowJo).
Blue Native PAGE
Detergent extraction using 0.5% C12E8 in 5 mM phosphate buffer containing 2 mM PMSF and 1% protease inhibitor cocktail (Calbiochem) was performed on 2×10 T120 erythroblasts per sample for 10 min on ice. Samples were centrifuged at 150,000 G for 30 min at 4°C and protein complexes from the extract separated using the Novex Native PAGE BisTris Blue Native polyacrylamide gel electrophoresis system (Thermo Fisher Scientific). Samples were run on 4%–16% gels with final sample concentration of 0.0625% Coomassie G and light blue cathode buffer-and transferred to PVDF membrane according to the manufacturer’s instructions.
Inhibition of lysosomal degradation
A combination of 10 μg/mL leupeptin, 10 μg/mL pepstatin A, 10 μg/mL E64d or DMSO alone was added to non-targeting control or ankyrin knockdown basophilic erythroblasts (T24) for 24 h in culture, then fixed for immunofluorescence or counted and processed for SDS PAGE and immunoblotting.
Cells were fixed for 15 min in 1% PFA + 0.0075% glutaraldehyde in PBSAG, allowed to adhere to 1% PEI coated coverslips, then labeled and imaged as previously described19 using a Leica SP5 AOBS confocal laser scanning microscope with 100× oil-immersion objective (NA 1.4).
Ankyrin is required for normal expression of multiple erythroid membrane and cytoskeletal proteins
To understand the essential role ankyrin plays in the assembly and maintenance of the human erythrocyte membrane, ankyrin-R was knocked down using shRNA lentivirally tranduced into CD34 cells isolated from healthy donor peripheral blood and then these cells were expanded and differentiated in vitro. Ankyrin knockdown of up to 95% was achieved and maintained in reticulocytes differentiated from erythroblasts expressing two independent shRNAs (Online Supplementary Figure S1). Analysis of protein expression by immunoblotting of total cell lysates derived from equal numbers of sorted ankyrin knockdown and control reticulocytes revealed reductions in the expression of cytoskeletal proteins spectrin and adducin, the membrane proteins CD47, CD44 and band 3 and strikingly large reductions in expression of protein 4.2 and RhAG (Figure 1A). Reductions in the reticulocyte expression of band 3 and GPA, and to a greater extent CD47, Rh, RhAG and CD44, were also observed by flow cytometry (Figure 1B).
Ankyrin is required for membrane protein retention during human erythroblast enucleation
Mislocalization of protein during enucleation has previously been suggested to account for protein loss based on confocal immunofluorescent imaging of nb/nb mouse erythroblasts undergoing enucleation.20 By staining differentiating ankyrin deficient erythroblasts grown in our human in vitro culture system with Hoechst and using a recently published flow cytometry gating strategy,18 protein partitioning profiles were determined for localization of specific membrane proteins within the plasma membrane of the reticulocyte and pyrenocyte (the extruded condensed nucleus encased by thin layer of cytoplasm and plasma membrane) derived from non-targeting control and ankyrin knockdown erythroblasts, respectively. The bar graphs in Figure 2A demonstrate that in the ankyrin deficient cultures there is an increase in the proportion of the ankyrin-R associated complex proteins band 3, GPA, RhAG, Rh and CD47 partitioning to the plasma membrane surrounding the extruded nucleus at this stage of differentiation. Interestingly, reduced reticulocyte plasma membrane retention was also observed for the junctional complex component GPC, as well as CD99, indicating that the effects of severe ankyrin deficiency extend beyond established ankyrin associated proteins. To confirm the mis-sorting of band 3 and GPA to the pyrenocyte during enucleation, sorted populations of reticulocytes and pyrenocytes were lysed and separated by SDS-PAGE. Figure 2B confirms the increased amount of GPA and band 3 in the pyrenocytes extruded from the ankyrin deficient erythroblasts relative to those from control erythroblasts. The remaining cytoskeletal adaptor protein 4.2 (the expression of which is reduced with severe depletion of ankyrin expression) is retained within the reticulocyte membrane and the membrane protein flotillin maintains the partitioning profile observed in healthy donor21 and non-targeting shRNA expressing cells. Similar experiments conducted using protein 4.2 knockdown cells did not result in reduced reticulocyte expression of Rh, RhAG or CD44 (data not shown), demonstrating that these effects are not an indirect consequence of the secondary protein 4.2 expression deficiency that occurs in response to ankyrin knockdown.
Importantly, although severe ankyrin-R deficiency results in an increase in the proportion of Rh and RhAG lost with the extruded pyrenocyte during enucleation as a percentage of total levels, absolute levels of these two proteins on the pyrenocytes derived from ankyrin knockdown erythroblasts are only minimally increased relative to control (Figure 2C). This observation highlights the fact that, although impaired reticulocyte retention of RhAG during erythroblast enucleation does occur in response to severe depletion of ankyrin, the majority of RhAG protein loss due to ankyrin-R deficiency must occur prior to enucleation.
Rhesus protein complex deficiency as a result of a loss of ankyrin occurs prior to erythroblast enucleation
To investigate the stage at which RhAG and other proteins are lost prior to enucleation in response to severe depletion of ankyrin-R expression, erythroblasts derived from CD34 cells transduced with non-targeting or ankyrin-R targeting shRNA were expanded and differentiated in vitro and protein expression examined at 24-h intervals by immunoblotting and flow cytometry. Representative cytospin images charting the morphological differentiation of control and ankyrin deficient erythroblasts are shown in Online Supplementary Figure S2. Figure 3A demonstrates that in the almost complete absence of ankyrin-R the cytoskeletal adaptor protein 4.2, which associates with band 3 early during erythropoiesis19 and is rapidly degraded in its absence, is strikingly reduced in its expression relative to non-targeting control vector transduced erythroblasts from the onset of terminal differentiation.
Surface expression of both band 3 and GPA was maintained at normal levels until the enucleation stage (Figure 3B). In contrast, a relative reduction in the expression of the Rh complex proteins Rh, RhAG and CD47 is observed from an early stage of differentiation, which in the case of Rh/RhAG becomes more pronounced as these proteins accumulate at the plasma membrane in the control erythroblasts. The expression profile and levels of GPC in erythroblasts transduced with ankyrin targeting shRNA was similar to control, although a reduction in the reticulocytes was observed by flow cytometry. Interestingly, the loss of ankyrin also caused a pronounced reduction in the steady state levels of transferrin receptor throughout terminal differentiation.
Rh/RhAG expression levels are prominently reduced in a panel of hereditary spherocytosis patients with confirmed ankyrin mutations
To determine whether the secondary membrane protein deficiencies identified in our in vitro derived ankyrin near null model are also observed in naturally occurring ankyrin deficient HS patients, we obtained a blood sample from a variety of patients with confirmed or suspected ankyrin mutations/deficiency. Although mutations in the gene encoding ankyrin-R (ANK1) are known to be responsible for HS in approximately 50% of cases, direct quantification of ankyrin deficiencies in the erythrocytes of these patients is notoriously laborious.17 To facilitate the assessment of the level of ankyrin deficiency in patient erythrocytes, we developed a protocol for the detection of ankyrin by flow cytometry using the monoclonal antibody BRIC272. The epitope that BRIC272 recognizes on ankyrin-R is not known but we have shown that it does not recognize the ANK90 binding domain (data not shown). Figure 4A and Online Supplementary Figure S3 demonstrate the variability in ankyrin expression within the healthy donor population as assessed using this technique which is consistent with that previously reported by radioactive immunoassay.17 This figure also shows expression of ankyrin relative to mean healthy donor controls in a random selection of patients available to us, and provides quantitative data that defines several mild and two severe deficiencies within this cohort.
Expression of major membrane proteins was assessed in these patients (Figure 4B). Note that despite the fact that ANK1 mutations (where known – additional details on the mutations are provided in the Online Supplementary Appendix) affect different regions of the ankyrin protein, a consistent significant reduction was observed in the surface expression of Rh and RhAG, as identified in our in vitro generated ankyrin knockdowns. This Rh/RhAG alteration is consistently prominent compared to the smaller reductions in expression of other proteins that reside within the ankyrin associated multiprotein complex including band 3 and GPA. No significant difference in the degree of RhAG reduction was observed between patients with mild and severe ankyrin deficiencies. In several patients, reduced expression of the ankyrin binding protein CD44 was also observed, although in others expression of this protein was decreased to only a mild degree. In contrast, erythrocytes from HS patients with differing clinical severity resulting from defined mutations in the genes encoding band 3 and protein 4.2 display increased or unaltered CD44 expression, respectively2522 (Online Supplementary Table S2).
To determine whether loss of Rh/RhAG also occurs prior to enucleation in naturally occurring ankyrin deficient patients, peripheral blood samples were obtained from a small number of ankyrin-R deficient HS patients with a range of clinical severities. Erythroblasts were expanded and differentiated in order to produce a population containing nucleated orthochromatic erythroblasts and reticulocytes. Consistent with the ankyrin-R knockdown results, Figure 4C demonstrates a substantially reduced surface expression of Rh/RhAG in orthochromatic erythroblasts of the more severely ankyrin deficient patient (approx. 43% normal ankyrin-R) prior to enucleation that is enhanced to only a minor degree by additional loss during enucleation. Surprisingly, despite obvious reductions in the expression of RhAG in the erythrocytes provided from mildly ankyrin deficient HS patients (Figure 4B), reductions in expression of this protein were not observed in the orthochromatic erythroblasts or (and to only a mild degree) in cultured reticulocytes from these patients.
Severe ankyrin-R deficiency abrogates tetrameric band 3 macrocomplex formation
Ankyrin can simultaneously bind to two dimers of band 3 via two distinct and co-operative sites located in the D2 and D3-4 domains forming the band 3 tetramer based core for a major membrane cytoskeletal multiprotein complex. We hypothesized that the dramatic reduction in surface expression of Rh complex components but not band 3 under conditions of severe ankyrin deficiency prior to enucleation indicated a requirement for band 3 tetramer formation for stable surface expression of these proteins that would be disrupted in the absence of ankyrin. Using Blue Native PAGE electrophoresis of C12E8 detergent extracts of healthy donor erythroblasts, we show for the first time using this approach that it is possible to distinguish two separate complexes containing band 3 (Figure 5A). Based on co-migration, the upper complex likely contains band 3, ankyrin, protein 4.2 and RhAG, and has a molecular weight consistent with the classical ankyrin associated band 3 tetrameric multiprotein complex. The second band 3, containing complex of lower molecular weight, likely represents the dimeric population of band 3. This population may be partially comprised of band 3 dissociated from tetrameric complexes during detergent extraction; however, immunoblotting with a GLUT1 specific antibody identified this protein to be present specifically within the region of the gel corresponding with dimeric band 3 and completely absent from that overlapping with the ankyrin associated tetrameric band 3 complex. This represents a novel demonstration that, despite its reported association with band 3,26 GLUT1 does not reside within the ankyrin associated complex of proteins in healthy donor erythroblast membranes. Figure 5B shows that detergent extracts from non-targeting control shRNA transduced erythroblasts have both the higher molecular weight (tetrameric) and smaller complexes of band 3 (two representative immunoblots shown for band 3), whereas in the severe ankyrin knockdown erythroblasts extracts only the lower molecular weight band 3 complex is detected.
RhAG loss in the absence of ankyrin occurs via lysosomal degradation
Reduced expression of RhAG in the absence or severe depletion of ankyrin could be accounted for by impaired delivery or a reduced stability at the plasma membrane. To explore the molecular mechanism that underlies reduced RhAG expression in the absence of ankyrin, pronase surface epitope recovery experiments were performed to assess the delivery efficiency of RhAG. Figure 6A shows that, following pronase treatment of control and ankyrin shRNA transduced erythroblasts, reappearance of the LA1818 epitope after a 1-h recovery period occurs to a similar degree in both control and ankyrin knockdown erythroblasts, indicating an equivalent level of delivery of RhAG to the plasma membrane in the presence and absence of ankyrin. Contrastingly, over a longer 2-h recovery time period, RhAG surface levels are reduced in the erythroblasts lacking ankyrin relative to control erythroblasts, suggesting an altered stability within the plasma membrane in the absence of ankyrin-R. In contrast, reappearance of band 3 BRIC6 epitopes following pronase treatment is increased after 1 h in ankyrin knockdown erythroblasts but not significantly different to control after 2-h recovery, possibly indicating a more rapid delivery of band 3 to the plasma membrane in the absence of ankyrin mediated band 3 tetramers. Confocal imaging of immunofluorescently labeled RhAG in ankyrin knockdown erythroblasts identified weak plasma membrane labeling of RhAG together with isolated intracellular clusters of RhAG labeling that co-localize with the lysosomal protein LAMP1, indicating localization of RhAG in a lysosomal compartment, which also appears enlarged/aggregated in these cells (Figure 6B). To confirm that reduced RhAG expression in ankyrin deficient erythroblasts results from lysosomal degradation of destabilized plasma membrane RhAG, cells were treated with a combination of lysosomal hydrolase inhibitors leupeptin, pepstatin A and E64d. Figures 6C and D show that treatment of ankyrin knockdown erythroblasts with this combination of lysosomal inhibitors results in an accumulation of RhAG that can be observed by immunofluorescence and immunoblotting of total cell lysates, demonstrating that loss of ankyrin causes lysosomal degradation of RhAG due to instability at the plasma membrane. Of note, we were unable to inhibit degradation of protein 4.2 in ankyrin knockdown erythroblasts using either lysosomal (leupeptin, pepstatin A, E64d), proteosomal (MG132) or calpain (calpain inhibitor I) inhibitors (data not shown). Protein 4.2 appears to be rapidly degraded in the absence of ankyrin, but in the presence of band 3 by an as yet undefined mechanism.
Using shRNA mediated knockdown in primary erythroblasts prior to terminal erythroid differentiation we have demonstrated the ability to deplete ankyrin-R expression by up to 95% generating an effective novel near null reticulocyte phenotype. As would be predicted, the reduction of ankyrin expression predominantly impacts the surface expression of membrane proteins assigned to the band 3 tetramer based erythrocyte multiprotein complex. The greatest impact of ankyrin deficiency is not on band 3 itself, however, but on the stability of the Rhesus protein sub complex (RhAG, Rh in particular), whether mediated by shRNA or by natural ankyrin genetic mutations. Importantly, reduced surface expression of the core Rh subcomplex components Rh and RhAG precedes the loss of the more extensively studied ankyrin binding protein band 3. We also demonstrate that absence of ankyrin during erythropoiesis abrogates the ability of band 3 to form the larger of two band 3-containing macrocomplexes (likely the band 3 tetrameric complex) detected by Blue Native PAGE. Protein 4.2, which fails to express at any stage of erythropoiesis in the absence of band 3 (but in the presence of ankyrin),18 is severely depleted in the absence of ankyrin at a stage of erythroid differentiation at which band 3 surface expression is unaltered, highlighting a reliance of protein 4.2 on the ankyrin mediated tetrameric organization specifically of band 3 for its stable expression. Interestingly severe depletion of ankyrin also impacts upon the reticulocyte expression of α/β spectrin and α adducin, highlighting the importance of this protein for stable maintenance of the wider erythroid cytoskeletal architecture.
A previous study that employed immunofluorescent staining of enucleating ankyrin deficient nb/nb murine erythroblasts attributed reduced expression of band 3, GPA and RhAG on the erythrocytes from this mouse to reduced retention of these proteins within the reticulocyte membrane during enucleation.20 The data presented here illustrate that, whilst band 3 and GPA do display increased partitioning to the pyrenocyte plasma membrane during human erythroblast enucleation, accounting for their reduced reticulocyte expression in the absence of ankyrin, the contribution of this mechanism to reduced reticulocyte RhAG expression is only minor. Intriguingly, we demonstrate that loss of the bulk of the core Rh subcomplex components, Rh and RhAG in the absence of ankyrin is temporally distinct from that of band 3/GPA, and in the case of RhAG, occurs via a distinct mechanism involving lysosomal degradation of unstable protein internalized post delivery to the plasma membrane during erythroblast differentiation. This mechanism of RhAG turnover likely also accounts for the loss of RhAG reported in Rhnull phenotype resulting from the p.(Asp399Ala) RhAG mutation within the putative ankyrin binding site,6 and is also consistent with the surprising stability of RhAG in the absence of band 3 during the early stages of terminal differentiation.18 Interestingly, ankyrin ‘near null’ reticulocytes exhibit a slightly greater reduction in the surface expression of Rh than that of RhAG. A population of RhAG is known to be capable of existing within the erythrocyte membrane independently of Rh.6 One possible explanation for this discrepancy in the levels of the Rh core components is that it is accounted for by a population of RhAG that is independent of both Rh and ankyrin, and achieves membrane stability via interaction with nontetrameric complex band 3. Importantly, Rh/RhAG but not band 3/GPA were also found to be dramatically decreased in the pre-enucleation orthochromatic erythroblasts of a naturally occurring HS patient with a 57% deficiency in ankyrin expression, demonstrating the relevance of observations made using our ‘near null’ model to understanding secondary protein loss in ankyrin deficient HS patients. The presence of RhAG at close to wild-type levels on orthochromatic erythroblasts and reticulocytes of mildly ankyrin deficient HS patients in spite of reduced erythrocyte expression is surprising. This observation highlights the difficulty in uncovering the basis of secondary protein loss in patients with missense ANK1 mutations that may retain misfolded or truncated protein products with potentially unpredictable effects, and suggests that additional protein loss must occur during reticulocyte remodeling and membrane shedding within the circulation of these patients. The fact that mild ankyrin deficiency appears to be well tolerated (at least in the early stages of erythroid differentiation), suggests that, initially, ankyrin exists in excess of that required for band 3 tetramer and Rh subcomplex stabilization. Nevertheless, the observation that the contribution of different mechanisms of secondary protein loss (pre and post enucleation) differs according to the degree of ankyrin deficiency in erythroid cells highlights important features for consideration of the role of ankyrin in membrane protein stability and remodeling at multiple stages in the ultimate development of a mature erythrocyte.
These data expand our understanding of the assembly of multiprotein complexes that occurs as part of erythroid membrane biogenesis during normal erythropoiesis, reveal the role of the cytoskeletal adaptor protein ankyrin-R, and describe the mechanism by which different associated proteins are lost during erythropoiesis. We propose the model summarized in Figure 7 for the assembly of the ankyrin associated multiprotein complex in which plasma membrane expression of Rh/RhAG is reliant upon stabilization by ankyrin. This likely occurs both indirectly through the formation of band 3 tetramers (further supported by the inability of the band 3 membrane domain to rescue reticulocyte expression of RhAG in an otherwise band 3 null environment)18 and through low affinity direct association of the C-terminus of RhAG with ankyrin, as previously suggested.6 Absence or severe reduction of ankyrin-R abrogates the formation of band 3 tetramers, resulting in expression of dimeric band 3 only, which results in the loss of protein 4.2 and the rapid internalization and lysosomal degradation of RhAG in differentiating erythroblasts post initial delivery to the plasma membrane. Dimeric band 3 and associated GPA are retained within the plasma membrane throughout the initial stages of erythropoiesis, but display increased partitioning to the pyrenocyte plasma membrane in the absence of cytoskeletal association via ankyrin. Reduced reticulocyte expression of other proteins reported here without established associations with ankyrin likely results both from reduced cytoskeletal association and increased loss of plasma membrane during enucleation and subsequent remodeling brought about by gross disruption of membrane cytoskeletal integrity in the absence of ankyrin.
Finally, mutations in the ANK1 gene are responsible for approximately 50% of HS cases in Europe and North America; however, current methods for identification and quantification of ankyrin deficiency are laborious and time consuming.17 In addition to the identification of consistently prominent reductions in the expression of the core Rh subcomplex proteins Rh and RhAG across a range of HS patients with ANK1 mutations, we report the application of a monoclonal anti-ankyrin antibody BRIC272 for the quantification of ankyrin expression using intracellular flow cytometry of permeabilized erythrocytes. We, therefore, propose that monitoring expression of Rh/RhAG and ankyrin levels directly by flow cytometry in patient’s erythrocytes provides a convenient screen for rapid preliminary identification and categorization of HS arising from mutations in ANK1.
The authors thank Dr. Andrew Herman and the University of Bristol Flow Cytometry Facility for assistance in performing fluorescence activated cell sorting, Dr. Paul Curnow (School of Biochemistry) for advice regarding Blue Native PAGE, Professor George Banting (School of Biochemistry) for provision of the CD99 monoclonal antibody (12E7) and Dr Rosey Mushens (Bristol Institute of Transfusion Medicine) for monoclonal antibodies.
- ↵* TJS and AJB contributed equally to this work.
- Check the online version for the most updated information on this article, online supplements, and information on authorship & disclosures: www.haematologica.org/content/101/9/1118
- Funding This work was supported by a Wellcome Trust project grant (094277) for TJS and a Wellcome Trust PhD studentship for AJB, KEM was supported by a BBSRC PhD DTG Case with Bristol Institute of Transfusion Sciences. This work was also funded in part by the National Institute for Health Research Blood and Transplant Research Unit (NIHR BTRU) in Red Blood Cell Products at the University of Bristol in partnership with NHS Blood and Transplant (NHSBT, AMT), and the European Community’s Seventh Framework Programme (FP7/2007–2013) under grant agreement 602121 (CoMMiTMenT-project, RvW). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health or NHSBT.
- Received March 14, 2016.
- Accepted May 25, 2016.
- Bennett V, Healy J. Membrane domains based on ankyrin and spectrin associated with cell-cell interactions. Cold Spring Harb Perspect Biology. 2009; 1(6):a003012. https://doi.org/10.1101/cshperspect.a003012Google Scholar
- Bennett V, Healy J. Organizing the fluid membrane bilayer: diseases linked to spectrin and ankyrin. Trends Mol Med. 2008; 14(1):28-36. PubMedhttps://doi.org/10.1016/j.molmed.2007.11.005Google Scholar
- Michaely P, Bennett V. The ANK repeats of erythrocyte ankyrin form two distinct but cooperative binding sites for the erythrocyte anion exchanger. J Biol Chem. 1995; 270(37):22050-22057. PubMedhttps://doi.org/10.1074/jbc.270.37.22050Google Scholar
- Kalomiris EL, Bourguignon LY. Mouse T lymphoma cells contain a transmembrane glycoprotein (GP85) that binds ankyrin. J Cell Biol. 1988; 106(2):319-327. PubMedhttps://doi.org/10.1083/jcb.106.2.319Google Scholar
- Nelson WJ, Veshnock PJ. Ankyrin binding to (Na+ + K+)ATPase and implications for the organization of membrane domains in polarized cells. Nature. 1987; 328(6130):533-536. PubMedhttps://doi.org/10.1038/328533a0Google Scholar
- Nicolas V, Le Van Kim C, Gane P. Rh-RhAG/ankyrin-R, a new interaction site between the membrane bilayer and the red cell skeleton, is impaired by Rh(null)-associated mutation. J Biol Chem. 2003; 278(28):25526-25533. PubMedhttps://doi.org/10.1074/jbc.M302816200Google Scholar
- Endeward V, Cartron JP, Ripoche P, Gros G. RhAG protein of the Rhesus complex is a CO2 channel in the human red cell membrane. FASEB J. 2008; 22(1):64-73. PubMedhttps://doi.org/10.1096/fj.07-9097comGoogle Scholar
- Geyer RR, Parker MD, Toye AM, Boron WF, Musa-Aziz R. Relative CO(2)/NH(3) permeabilities of human RhAG, RhBG and RhCG. J Membr Biol. 2013; 246(12):915-926. PubMedhttps://doi.org/10.1007/s00232-013-9593-0Google Scholar
- Cartron JP. RH blood group system and molecular basis of Rh-deficiency. Baillieres Best Pract Res Clin Haematol. 1999; 12(4):655-689. PubMedhttps://doi.org/10.1053/beha.1999.0047Google Scholar
- Tse WT, Lux SE. Red blood cell membrane disorders. Br J Haematol. 1999; 104(1):2-13. PubMedhttps://doi.org/10.1111/j.1365-2141.1999.01130.xGoogle Scholar
- Eber SW, Gonzalez JM, Lux ML. Ankyrin-1 mutations are a major cause of dominant and recessive hereditary spherocytosis. Nature Genet. 1996; 13(2):214-218. PubMedhttps://doi.org/10.1038/ng0696-214Google Scholar
- Perrotta S, Gallagher PG, Mohandas N. Hereditary spherocytosis. Lancet. 2008; 372(9647):1411-1426. PubMedhttps://doi.org/10.1016/S0140-6736(08)61588-3Google Scholar
- Jarolim P, Rubin HL, Brabec V, Palek J. A nonsense mutation 1669Glu–>Ter within the regulatory domain of human erythroid ankyrin leads to a selective deficiency of the major ankyrin isoform (band 2.1) and a phenotype of autosomal dominant hereditary spherocytosis. J Clin Invest. 1995; 95(3):941-947. PubMedhttps://doi.org/10.1172/JCI117802Google Scholar
- Iolascon A, Miraglia del Giudice E, Camaschella C. Ankyrin deficiency in dominant hereditary spherocytosis: report of three cases. Br J Haematol. 1991; 78(4):551-554. PubMedhttps://doi.org/10.1111/j.1365-2141.1991.tb04487.xGoogle Scholar
- Lanciotti M, Perutelli P, Valetto A, Di Martino D, Mori PG. Ankyrin deficiency is the most common defect in dominant and non dominant hereditary spherocytosis. Haematologica. 1997; 82(4):460-462. PubMedGoogle Scholar
- Rank G, Sutton R, Marshall V. Novel roles for erythroid Ankyrin-1 revealed through an ENU-induced null mouse mutant. Blood. 2009; 113(14):3352-3362. PubMedhttps://doi.org/10.1182/blood-2008-08-172841Google Scholar
- Savvides P, Shalev O, John KM, Lux SE. Combined spectrin and ankyrin deficiency is common in autosomal dominant hereditary spherocytosis. Blood. 1993; 82(10):2953-2960. PubMedGoogle Scholar
- Satchwell TJ, Hawley BR, Bell AJ, Ribeiro ML, Toye AM. The cytoskeletal binding domain of band 3 is required for multiprotein complex formation and retention during erythropoiesis. Haematologica. 2015; 100(1):133-142. PubMedhttps://doi.org/10.3324/haematol.2014.114538Google Scholar
- Satchwell TJ, Bell AJ, Pellegrin S. Critical band 3 multiprotein complex interactions establish early during human erythropoiesis. Blood. 2011; 118(1):182-191. PubMedhttps://doi.org/10.1182/blood-2010-10-314187Google Scholar
- Salomao M, Chen K, Villalobos J, Mohandas N, An X, Chasis JA. Hereditary spherocytosis and hereditary elliptocytosis: aberrant protein sorting during erythroblast enucleation. Blood. 2010; 116(2):267-269. PubMedhttps://doi.org/10.1182/blood-2010-02-264127Google Scholar
- Bell AJ, Satchwell TJ, Heesom KJ. Protein distribution during human erythroblast enucleation in vitro. PloS one. 2013; 8(4):e60300. PubMedhttps://doi.org/10.1371/journal.pone.0060300Google Scholar
- Bruce LJ, Beckmann R, Ribeiro ML. A band 3-based macrocomplex of integral and peripheral proteins in the RBC membrane. Blood. 2003; 101(10):4180-4188. PubMedhttps://doi.org/10.1182/blood-2002-09-2824Google Scholar
- Toye AM, Williamson RC, Khanfar M. Band 3 Courcouronnes (Ser667Phe): a trafficking mutant differentially rescued by wild-type band 3 and glycophorin A. Blood. 2008; 111(11):5380-5389. PubMedhttps://doi.org/10.1182/blood-2007-07-099473Google Scholar
- Bruce LJ, Ghosh S, King MJ. Absence of CD47 in protein 4.2-deficient hereditary spherocytosis in man: an interaction between the Rh complex and the band 3 complex. Blood. 2002; 100(5):1878-1885. PubMedhttps://doi.org/10.1182/blood-2002-03-0706Google Scholar
- van den Akker E, Satchwell TJ, Pellegrin S. Investigating the key membrane protein changes during in vitro erythropoiesis of protein 4.2 (−) cells (mutations Chartres 1 and 2). Haematologica. 2010; 95(8):1278-1286. PubMedhttps://doi.org/10.3324/haematol.2009.021063Google Scholar
- Jiang W, Ding Y, Su Y, Jiang M, Hu X, Zhang Z. Interaction of glucose transporter 1 with anion exchanger 1 in vitro. Biochem Biophys Res Commun. 2006; 339(4):1255-1261. PubMedhttps://doi.org/10.1016/j.bbrc.2005.11.138Google Scholar